Head to Head Review: Unicycive Therapeutics (NASDAQ:UNCY) and Tonix Pharmaceuticals (NASDAQ:TNXP)

Unicycive Therapeutics (NASDAQ:UNCY) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Valuation and Earnings

This table compares Unicycive Therapeutics and Tonix Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	221.85	-$36.73 million	($3.95)	-1.78
Tonix Pharmaceuticals	$10.09 million	22.06	-$130.04 million	($20.06)	-0.91

Unicycive Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Unicycive Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Unicycive Therapeutics and Tonix Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	0	3	0	2.50
Tonix Pharmaceuticals	1	0	2	0	2.33

Unicycive Therapeutics presently has a consensus target price of $34.33, suggesting a potential upside of 389.08%. Tonix Pharmaceuticals has a consensus target price of $70.00, suggesting a potential upside of 282.72%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Tonix Pharmaceuticals.

Insider & Institutional Ownership

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-227.32%	-117.71%
Tonix Pharmaceuticals	-963.39%	-55.19%	-49.89%

Summary

Unicycive Therapeutics beats Tonix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company’s rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.